Recombinant Human RASSF3 protein

RASSF3 (Ras Association Domain Family Member 3) is a member of the RASSF protein family, which is characterized by conserved Ras association (RA) domains and plays diverse roles in tumor suppression, apoptosis, and cellular signaling. Unlike other RASSF members (e.g., RASSF1A), RASSF3 lacks a C-terminal Salvador/RASSF/Hippo (SARAH) domain but retains the RA domain, enabling interactions with small GTPases like Ras and Rap. It is ubiquitously expressed and localizes to both the cytoplasm and nucleus, participating in multiple pathways, including the Hippo, p53. and NF-κB signaling networks.

Recombinant RASSF3 protein is typically produced using bacterial (e.g., *E. coli*) or eukaryotic (e.g., HEK293. insect cells) expression systems to study its structural and functional properties. The recombinant form often includes affinity tags (e.g., His-tag, GST) for purification and detection. Studies using recombinant RASSF3 have revealed its role as a tumor suppressor by promoting apoptosis, inhibiting cell proliferation, and regulating the cell cycle. It stabilizes p53 by counteracting MDM2-mediated degradation and modulates the Hippo pathway by interacting with core components like MST1/2. influencing YAP/TAZ activity.

RASSF3 also participates in DNA damage response and oxidative stress regulation. Its dysregulation is linked to cancers, including breast, lung, and colorectal carcinomas, where reduced expression correlates with poor prognosis. Paradoxically, RASSF3 exhibits context-dependent oncogenic traits in certain malignancies, highlighting its complex regulatory mechanisms. Recombinant RASSF3 serves as a critical tool for elucidating these dual roles, enabling biochemical assays (e.g., protein-protein interaction studies) and therapeutic target exploration. Further research aims to clarify its tissue-specific functions and potential as a biomarker or therapeutic target in precision oncology.